InvestorsHub Logo
Followers 145
Posts 27554
Boards Moderated 3
Alias Born 02/07/2004

Re: midastouch017 post# 198

Friday, 04/28/2017 8:38:31 AM

Friday, April 28, 2017 8:38:31 AM

Post# of 651

The Company announced positive preliminary safety results from the Phase 2b clinical trial of M-001, conducted in collaboration with the European UNISEC consortium[1]. Immunogenicity results, currently being processed by other UNISEC consortium entities, are expected by the end of Q2 2017.



Not too long a wait!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BVXV News